Evidence map›Paper›PMID 24566854›Full record

ArticleInternational journal of obesity (2005)2014

4β-Hydroxywithanolide E isolated from Physalis pruinosa calyx decreases inflammatory responses by inhibiting the NF-κB signaling in diabetic mouse adipose tissue.

T Takimoto, Y Kanbayashi, T Toyoda, Y Adachi, C Furuta, K Suzuki, T Miwa, M Bannai

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of obesity (2005), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
8.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. A review of nutritional properties and health benefits of Physalis species.Plant foods for human nutrition (Dordrecht, Netherlands) · 2020
    Review
  6. Article
  7. Article
  8. Molecules (Basel, Switzerland) · 2019
    Article
  9. Article
  10. Article
  11. Natural Withanolides in the Treatment of Chronic Diseases.Advances in experimental medicine and biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

T TakimotoFrontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan.
Y KanbayashiFrontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan.
T ToyodaFrontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan.
Y AdachiFrontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan.
C FurutaFrontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan.
K SuzukiFrontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan.
T MiwaFrontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan.
M BannaiFrontier Research Laboratories, Institute for Innovation, Ajinomoto Co., Inc., Kawasaki-Ku, Kawasaki, Japan.
Ajinomoto (Japan) · JPAjinomoto (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic inflammation in adipose tissue together with obesity induces insulin resistance. Inhibitors of chronic inflammation in adipose tissue can be a potent candidate for the treatment of diabetes; however, only a few compounds have been discovered so far. The objective of this study was to find a novel inhibitor that can suppress the inflammatory response in adipose tissue and to elucidate the intracellular signaling mechanisms of the compound.

methodsTo find the active compounds, we established an assay system to evaluate the inhibition of induced MCP-1 production in adipocyte/macrophage coculture in a plant extract library. The active compound was isolated by performing high-performance liquid chromatography (HPLC) and was determined as 4β-hydroxywithanolide E (4βHWE) by nuclear magnetic resonance (NMR) and mass spectroscopy (MS) spectral analyses. The effect of 4βHWE on inflammation in adipose tissue was assessed with adipocyte culture and db/db mice.

resultsDuring the screening process, Physalis pruinosa calyx extract was found to inhibit production of MCP-1 in coculture strongly. 4βHWE belongs to the withanolide family of compounds, and it has the strongest MCP-1 production inhibitory effect and lowest toxicity than any other withanolides in coculture. Its anti-inflammatory effect was partially dependent on the attenuation of NF-κB signaling in adipocyte. Moreover, in vivo experiments showed that the oral administration of 4βHWE to db/db mice resulted in the inhibition of macrophage invasion and cytokine expression in adipose tissue after 2 weeks of treatment; improved the plasma adiponectin, non-esterified fatty acids and MCP-1 concentrations; and increased glucose tolerance after 3 to 4 weeks of treatment.

conclusionsThese results suggest that 4βHWE has anti-inflammatory effect via inhibition of NF-κB activation in adipocyte. Moreover, the attenuation of inflammation in adipocyte has an effect on the inhibition of macrophage accumulation in obese adipose tissue. Consequently, 4βHWE improves impaired glucose tolerance. Thus, 4βHWE is a useful natural anti-inflammatory compound to attenuate progression of diabetes and obesity.

Indexed as

3T3-L1 CellsAdipocytesAdipose TissueAnimalsChemokine CCL2Chromatography, High Pressure LiquidCoculture TechniquesGlucoseImmunoblottingInflammationInsulin ResistanceMacrophagesMaleMass SpectrometryMiceMice, Inbred NOD4-hydroxywithanolide ECcl2 protein, mouseChemokine CCL2GlucoseNF-kappa BPlant ExtractsWithanolides

Identifiers

PMID24566854
OpenAlexW2042421606

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.